期刊
CANCER TREATMENT REVIEWS
卷 41, 期 8, 页码 680-689出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2015.05.007
关键词
Non-Hodgkin Lymphomas; Rituximab; Monoclonal antibodies; CD20; Apoptosis
类别
资金
- Fundacion Investigacion Biomedica Puerta de Hierro
- iPFIS fellowship from Institut de Salud Carlos III (ISCIII)-Fondos FEDER, Plan Estatal I+D+I [IFI14/00003]
- Miguel Servet Contract from ISCIII-Fondos FEDER, Plan Nacional I+D+I, Ministerio de Economia y Competitividad (MINECO) [CP11/00018]
Anti-CD20 monoclonal antibodies (mAbs) have improved patient's survival with Non-Hodgkin Lymphoma, when combined with chemotherapy. Several mechanisms of action have been reported, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and induction of apoptosis. Despite the large amount of studies and published data, the role each mechanism played in vivo is not fully understood. Furthermore, the reason why a significant percentage of patients are refractory or resistant remains unknown. Several activated intracellular signaling pathways have been implicated in the mechanisms of resistance of rituximab. In the present manuscript, we review those mechanisms and new anti-CD20 mAbs, as well as the efforts being accomplished to overcome it, focusing on new drugs targeting pathways implicated in resistance to rituximab. (C) 2015 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据